ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1739

What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?

Jessica Zhu1, Craig Gale2, Joshua Biber3, Mandana Nikpour4, Murray Baron5 and Tracy M. Frech6, 1School of Medicine, University of Utah, Salt Lake City, UT, 2Bioinformatics, University of Utah, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT, 4The University of Melbourne, Melbourne, Australia, Melbourne, Australia, 5Department of Medicine, McGill University, Montreal, QC, Canada, 6Division of Rheumatology, University of Utah, Salt Lake City, UT

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: gastrointestinal complications, patient outcomes and systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: Systemic Sclerosis and Related Disorders – Clinical Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice.  The use of gastrointestinal (GI) PROMs is particularly important in systemic sclerosis (SSc), especially for the identification of small intestinal bacterial overgrowth (SIBO), where hydrogen breath testing for definitive diagnosis is difficult to perform.  In this report, we examine the clinical correlates of two validated GI PROM scores in SSc to inform the design of a pragmatic trial in SSc SIBO.

Methods: Patients seen at a single center SSc Clinic, who met the 2013 ACR/EULAR Criteria and were enrolled in the INSYNC registry received an electronic link to a personal health assessment questionnaire that included the Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract (GIT 2.0) and gastrointestinal global symptom score (GSS), which have previously been validated in the SSc population. The GIT 2.0 (34 questions) provides a total score of GIT severity, and is calculated by an average of all scales (questions 1-8 reflux, 9-12 distention/boating, 13 soilage, 14-15 diarrhea, 16-21 social function, 22-30 emotional well-being, 31-34 constipation), except constipation.  The scores range from mild (0-0.49) to severe-to very-severe (1.01-3). The GSS assesses nausea, vomiting, abdominal pain/discomfort, bloating, diarrhea, constipation, abdominal tenderness, dysuria, tenesmus, fever and general illness/malaise, with each symptom scored from 0 (absent) to 3 (severe). It has previously been reported in the SSc population that a GSS ≥ 5 is predictive of SIBO. We compared the GIT 2.0 scores in those with GSS <5 and ≥ 5, using the t-test, with significance set at 5%.

Results:  From January to May 2018, 43 SSc patients completed both the SCTC GIT 2.0 and GSS (59 % completion rate).  These patients were 95% female, 67% limited cutaneous subtype, 73% scleroderma-specific autoantibodies (40.5% centromere, 13.5% SCL70, 18.9% RNApol3), with an average disease duration of 13.5 years. The subscales of GIT 2.0 according to GSS are shown in Table 1. As expected the potential SIBO patients with a GSS ≥ 5 had significantly more distention/bloating (p=0.001), but unexpectedly more constipation (p=0.04) on the GIT 2.0. 

Conclusion:  Gastrointestinal complaints are common in SSc and PROM questionnaires are an essential aspect of care, but the optimal number of questions and mode of questionnaire delivery are important as evidenced by our completion rate. If a GSS ≥ 5 represents SIBO, then this study suggests that subscales of the GIT 2.0 may be able to effectively capture this disease entity. The social functioning and emotional well-being domains of GIT 2.0 warrant further study in SIBO patients.

Table 1: Subscales of the GIT 2.0 according to GSS (with > 5 possibly identifying SIBO)

GIT 2.0 Subscales

GSS ≥ 5  (n=24)

GSS < 5 (n=19)

p-value

Reflux

0.83

0.46

0.051

Distention/Bloating

1.28

0.57

0.001

Diarrhea

0.65

0.34

0.093

Social

0.56

0.13

0.002

Emotional

0.65

0.15

0.001

Constipation

0.67

0.29

0.043

Soilage

0.33

0.11

0.171



Disclosure: J. Zhu, None; C. Gale, None; J. Biber, None; M. Nikpour, Actelion, GSK, Pfizer, BMS, Eli Lilly, UCB, Astra Zeneca, Janssen, 2, 5; M. Baron, None; T. M. Frech, None.

To cite this abstract in AMA style:

Zhu J, Gale C, Biber J, Nikpour M, Baron M, Frech TM. What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/what-do-patient-reported-outcomes-for-routine-monitoring-of-gastrointestinal-tract-symptoms-in-a-systemic-sclerosis-center-tell-us-about-clinical-features-of-potential-small-intestinal-bacterial-overg/. Accessed January 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-do-patient-reported-outcomes-for-routine-monitoring-of-gastrointestinal-tract-symptoms-in-a-systemic-sclerosis-center-tell-us-about-clinical-features-of-potential-small-intestinal-bacterial-overg/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.